Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
BMJ Mil Health ; 169(4): 355-358, 2023 Aug.
Article in English | MEDLINE | ID: mdl-35131888

ABSTRACT

BACKGROUND: Prolonged field care is required when casualty evacuation to a surgical facility is delayed by distance, weather or tactical constraints. This situation can occur in both civilian and military environments. In these circumstances, there are no established treatment options for extremity compartment syndrome. Telementoring by a surgeon may enable the local clinician to perform a fasciotomy to decompress the affected compartments. METHODS: Six military clinicians were asked to perform a two-incision leg fasciotomy in synthetic models under the guidance of an orthopaedic surgeon located 380 km away. Communication occurred through commercially available software and smartglasses, which also allowed the surgeon to send augmented-reality graphics to the operators. Two blinded surgeons evaluated the specimens according to objective criteria. Control specimens were added to ensure the integrity of the evaluation process. RESULTS: The six study participants were military physician assistants who had extensive clinical experience but had never performed a fasciotomy. The average duration of the procedure was 53 min. All six procedures were completed without major errors: release of all four compartments was achieved through full-length incisions in the skin and fascia. The only surgical complication was a laceration of the saphenous vein. All three control specimens were correctly assessed by the evaluators. None of the participants experienced adverse effects from wearing the smartglasses. Four dropped calls occurred, but the connection was re-established in all cases. CONCLUSION: All six surgical procedures were completed successfully. We attribute the dropped calls to a mismatch between the size of the graphic files and the available bandwidth. A better technical understanding of the software by the mentoring surgeon would have avoided this problem. Important considerations for future research and practice include protocols for dropped communications, surgical skills training for the operators and communication training for the surgeons.


Subject(s)
Mentoring , Surgeons , Humans , Leg , Fasciotomy/methods , Mentoring/methods
2.
BMJ Mil Health ; 167(2): 114-117, 2021 Apr.
Article in English | MEDLINE | ID: mdl-32123001

ABSTRACT

Tactical combat casualty care and the application of extremity tourniquets have saved lives in combat. In the modern combat environment junctional injuries are common and difficult to treat. Recently, junctional tourniquets have emerged as a potential solution to this problem. Junctional tourniquets can be used as an adjunct to persistent haemorrhage despite application of conventional tourniquets or in the persistently hypotensive casualty. Surgeons must have an approach to receiving patients with junctional tourniquets in place in the operating room. The algorithms presented allow for an evidence-based and command-driven implantation of junctional tourniquets as part of tactical combat casualty care.


Subject(s)
Extremities/surgery , Hemorrhage/therapy , Warfare/trends , Extremities/injuries , Hemorrhage/classification , Hemorrhage/prevention & control , Humans , Military Medicine/methods , Operating Rooms/methods , Operating Rooms/trends , Tourniquets/standards
3.
J R Army Med Corps ; 2017 Aug 09.
Article in English | MEDLINE | ID: mdl-28794007

ABSTRACT

Damage control resuscitation and early thoracotomy have been used to increase survival after severe injury in combat. There has been a renewed interest in resuscitative endovascular balloon occlusion of the aorta (REBOA) in both civilian and military medical practices. REBOA may result in visceral and limb ischaemia that could be harmful if use of REBOA is premature or prolonged. The purpose of this paper is to align our experience of combat injuries with the known capability of REBOA to suggest an implementation strategy for the use of REBOA in combat care. It may replace the resuscitative effect of thoracotomy; can provide haemostasis of non-compressible torso injuries such as the junctional and pelvic haemorrhage caused by improvised explosive devices. However, prehospital use of REBOA must be in the context of an overall surgical plan and should be restricted to deployment in the distal aorta. Although REBOA is technically easier than a thoracotomy, it requires operator training and skill to add to the beneficial effect of damage control resuscitation and surgery.

4.
Can J Gastroenterol ; 25(10): 565-9, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22059162

ABSTRACT

BACKGROUND: Little is known about physician perceptions of and practices in using infliximab - a biological agent that was approved in Canada for the treatment of Crohn's disease in 2001, and for ulcerative colitis in 2006. OBJECTIVES: To describe Canadian gastroenterologists' use and perceptions of infliximab in the treatment of refractory inflammatory bowel disease (IBD), and to identify factors that may influence a gastroenterologist's decision to initiate infliximab therapy. METHODS: A postal questionnaire was distributed to all practicing clinicians captured in the 2007 membership of the Canadian Association of Gastroenterology. Each physician was contacted up to a maximum of three times. RESULTS: Of 466 questionnaires mailed out, responses were received from 336 (72%), with 292 respondents (63%) returning fully completed surveys. For 80% of respondents, IBD patients comprised less than 30% of their clinical practice. Most prescribed infliximab at an initial dose of 5 mg/kg (97%), prescribed loading doses at 0, 2 and 6 weeks (88%), premedicated with corticosteroids (74%), administered maintenance infusions at eight-week intervals (89%), co-administered immunosuppressive agents (81%) and continued infliximab 'indefinitely' as long as it was effective and well tolerated (76%). Most gastroenterologists (>70%) identified lack of drug insurance coverage and provincial funding criteria as important barriers to prescribing infliximab. CONCLUSIONS: Most Canadian gastroenterologists exhibited similar practice patterns with respect to the use of infliximab for induction and maintenance therapy of IBD. Common barriers to the initiation of infliximab therapy were identified.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Practice Patterns, Physicians' , Adult , Aged , Canada , Crohn Disease/drug therapy , Drug Utilization , Female , Gastroenterology/statistics & numerical data , Humans , Infliximab , Male , Middle Aged
5.
Chronic Dis Can ; 29(2): 80-8, 2009.
Article in English | MEDLINE | ID: mdl-19281693

ABSTRACT

Many cancer patients seek complementary therapies (CTs) for cancer management; however, relatively little is known about patients' CT information seeking behaviour. Therefore, we assessed: 1) cancer patients' use of the types and sources of CT information; 2) their information preferences; and 3) their understanding of the phrase "scientific evidence or proof that a therapy works." We collected data from 404 patients attending the Tom Baker Cancer Centre (TBCC) in Calgary and 303 patients calling the Cancer Information Service (CIS) helpline. In most cases, patients wanted information on the safety of CTs, how CTs work and their potential side effects. Physicians and conventional cancer centres were the most desired sources of CT information, but relatively few patients obtained information via these sources. Although patients were aware of the meaning of scientific evidence, they often used information based on non-scientific evidence, such as patient testimonials. The creation of a supportive care environment in conventional cancer treatment centres, by providing CT information, may help address cancer patients' concerns and alleviate some of the stress that may have been caused by the cancer diagnosis.


Subject(s)
Needs Assessment/organization & administration , Neoplasms/psychology , Patient Acceptance of Health Care/psychology , Patient Education as Topic/organization & administration , Adult , Aged , Aged, 80 and over , Alberta , Chi-Square Distribution , Choice Behavior , Complementary Therapies/education , Complementary Therapies/psychology , Complementary Therapies/statistics & numerical data , Female , Health Knowledge, Attitudes, Practice , Hotlines , Humans , Male , Middle Aged , Neoplasms/prevention & control , Patient Acceptance of Health Care/statistics & numerical data , Qualitative Research , Safety , Socioeconomic Factors , Surveys and Questionnaires
6.
Can J Gastroenterol ; 22(11): 931-6, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19018339

ABSTRACT

BACKGROUND: Gastric variceal bleeding is associated with significant morbidity and mortality in patients with portal hypertension. Outside of North America, gastric variceal injection of N-butyl-2-cyanoacrylate has been shown to be safe and effective. The majority of studies on this mode of therapy are in Asian populations in which the etiology of portal hypertension differs from North America. AIM: To assess the safety and efficacy of gastric variceal glue injection in a North American population. METHODS: Consecutive patients that underwent glue injection of gastric varices in the Calgary Health Region from 2001 to 2006 were assessed. RESULTS: Thirty-four patients (19 men, 15 women) underwent a total of 47 separate gluing procedures. Of those presenting with active bleeding at endoscopy, immediate hemostasis was achieved in 93.8% of patients. Rebleeding within 48 h of gluing was observed after four procedures. Gastric varices were eradicated in 84.0% of cases. Complications included superior mesenteric vein thrombosis in one patient. Twenty-eight (82.4%) patients were alive at the end of follow-up. The treatment failure-related mortality rate was 2.1%. CONCLUSIONS: The present study is one of the few to assess the role of gastric variceal gluing in a North American population. Glue injection with cyanoacrylate is safe and effective in the treatment of bleeding gastric varices.


Subject(s)
Enbucrilate/administration & dosage , Endoscopy, Gastrointestinal/methods , Esophageal and Gastric Varices/therapy , Gastrointestinal Hemorrhage/therapy , Hemostasis, Endoscopic/methods , Adult , Aged , Alberta/epidemiology , Esophageal and Gastric Varices/complications , Esophageal and Gastric Varices/epidemiology , Female , Follow-Up Studies , Gastrointestinal Hemorrhage/epidemiology , Gastrointestinal Hemorrhage/etiology , Humans , Incidence , Injections, Intralesional , Male , Middle Aged , Retrospective Studies , Stomach , Treatment Outcome , Urban Population
7.
J Cyst Fibros ; 7(1): 1-6, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17766191

ABSTRACT

The life expectancy for cystic fibrosis (CF) patients has increased dramatically over the last 30 years. Although the overall cancer risk for CF patients does not appear to be increased there is a marked increased risk of gastrointestinal malignancies especially in the post lung transplant population. CF patients that do develop gastrointestinal malignancies do so at an earlier age and there is often a lag in the diagnosis and management of these individuals. We present a 39 year old male CF patient that underwent a colonoscopy for colon cancer screening and a large, near obstructing, villous adenoma of his ileum was found. The polyp was removed successfully via endoscopy without incident and there was no evidence of malignancy. An upper endoscopy revealed a long segment of Barrett's esophagus with no evidence of dysplasia. We present this case as well as a detailed review of the literature on cancer risk in CF and a discussion of the mechanisms that may be involved. We also present the risk of GI malignancies in non-CF patients as a guide on how to assess and manage the risk of GI malignancies in this ever-changing patient population.


Subject(s)
Adenoma, Villous/complications , Barrett Esophagus/complications , Cystic Fibrosis/complications , Ileal Neoplasms/complications , Adenoma, Villous/pathology , Adult , Barrett Esophagus/pathology , Colonoscopy , Endoscopy, Gastrointestinal , Genetic Predisposition to Disease , Humans , Ileal Neoplasms/pathology , Male , Risk Factors
8.
Can J Gastroenterol ; 21(12): 843-6, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18080058

ABSTRACT

PURPOSE: To determine who provides gastrointestinal endoscopy in Canada and to understand provincial and regional differences in endoscopy providers. METHODS: Aggregate physician sociodemographic and activity data for 2002 were obtained from the Canadian Institute of Health Information's National Physician Database. Physicians were classified as gastroenterologists, general surgeons and others. RESULTS: In 2002, 1444 physicians, including 735 surgeons, 551 gastroenterologists and 158 others, performed at least 100 colonoscopies or 100 gastroscopies. Gastroenterologists performed 53% of all colonoscopies and 59% of all gastroscopies. Gastroenterologists were the primary providers of colonoscopies in large urban areas, whereas surgeons were the primary providers in smaller urban and rural areas. An average of 317 colonoscopies were performed by surgeons, 516 by gastroenterologists and 203 by other physicians. The proportion of surgeon colonoscopists in each province ranged from 47% to 71%. CONCLUSIONS: Surgeons and gastroenterologists are the major providers of gastrointestinal endoscopy in Canada, but the distribution of these providers among provinces and urban and rural areas varies. Although surgeon endoscopists are more numerous, on average, they perform fewer procedures annually than internists.


Subject(s)
Endoscopy, Gastrointestinal/statistics & numerical data , Practice Patterns, Physicians' , Canada , Humans
9.
Dig Liver Dis ; 38(1): 60-3, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16216567

ABSTRACT

The potential for qualitative research in the field of inflammatory bowel disease has been overlooked due to a misunderstanding of the methods and intent of this approach. In this paper, we provide a brief overview of qualitative research and address some of the misconceptions and criticisms that we have come across during our use of qualitative research methods in inflammatory bowel disease research.


Subject(s)
Inflammatory Bowel Diseases/etiology , Humans , Research Design , Sample Size
10.
Complement Ther Med ; 11(1): 22-7, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12667971

ABSTRACT

OBJECTIVE: In this paper we present emergent categories of factors that influence inflammatory bowel disease patients' decisions to use complementary therapies and discuss similarities between this work and existing models of care. METHODS: This combined methods study consisted of a quantitative survey followed by qualitative interviews. The results of the qualitative interviews are reported in this article. RESULTS: Major categories that emerged during qualitative analysis were the personal context (i.e. contextual issues that influenced the individual's experience of illness), impact (i.e. the impact that the experience of illness had on the individual), and action (i.e. actions taken to manage the individual's illness). DISCUSSION: Research in the areas if complementary therapy, biopsychosocial models, and patient-centered care, point to the importance of patient-physician communication. Our findings with people who have inflammatory bowel disease are in alignment with this previous body of work. By investigating the reasons for using complementary therapies among people who have a chronic illness, we make a substantive contribution to a growing body of literature that supports the need for continued emphasis on strengthening patient-physician relationships.


Subject(s)
Complementary Therapies/psychology , Inflammatory Bowel Diseases/psychology , Inflammatory Bowel Diseases/therapy , Patient Acceptance of Health Care/psychology , Adult , Canada , Female , Humans , Interviews as Topic , Male , Middle Aged , Physician-Patient Relations , Social Support , Surveys and Questionnaires
11.
Am J Gastroenterol ; 96(10): 2934-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11693329

ABSTRACT

OBJECTIVE: Increased small intestinal permeability has been found in patients with Crohn's disease and in a proportion of their healthy relatives. This may reflect a shared environment or shared genes. The finding of abnormal permeability in the healthy spouses of patients would favor an environmental cause for this observation. METHODS: The healthy spouses of patients with Crohn's disease attending three gastroenterology clinics were invited to participate. Eligible subjects consumed a 350-ml solution containing lactulose, mannitol, and sucrose before bedtime. All overnight urine was collected, assayed by high performance liquid chromatography, and the ratio of fractional excretion of lactulose to mannitol was calculated as an index of permeability. The results were compared with those of a previously determined control group. RESULTS: Sixty spouses completed the study. Increased permeability was present in eight (13.3%, 95% CI = 6.0-24.6%). The presence of increased permeability was not related to age, gender, duration of cohabitation, alcohol use, nonsteroidal anti-inflammatory drug use or to disease activity in the patient with Crohn's disease. There was a nonsignificant trend for abnormal permeability to occur in those spouses cohabiting with the patient with Crohn's disease at the time of disease diagnosis (p = 0.128). CONCLUSIONS: Small intestinal permeability is increased in a proportion of healthy spouses of patients with Crohn's disease. The presence of abnormal permeability studies in patients with Crohn's disease and a proportion of their healthy close contacts suggests that this phenomenon is caused by environmental factors.


Subject(s)
Crohn Disease/metabolism , Intestinal Absorption , Intestinal Mucosa/metabolism , Adult , Crohn Disease/etiology , Crohn Disease/physiopathology , Environmental Health , Female , Humans , Male , Middle Aged , Permeability , Reference Values , Spouses
12.
J Viral Hepat ; 8(4): 249-55, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11454175

ABSTRACT

The progression of fibrosis in chronic hepatitis C infection (HCV) is related to host factors including age, gender and alcohol consumption. Due to the morbidity and potential mortality of liver biopsy, a noninvasive method of assessing hepatic fibrosis is needed. The aim of this study was to assess the utility of historical features in predicting fibrosis using published rates of fibrosis progression. The charts of 239 untreated patients with HCV were reviewed; patients who had a liver biopsy and whose duration of infection could be estimated (n=106) were categorized according to gender, age at infection (< or = or > 40 years) and peak alcohol consumption (< or > or = 50 g/day). Estimates of fibrosis were calculated using the product of the interval between infection and biopsy and published rates of fibrosis progression. Estimates were compared with liver biopsies staged according to the Metavir system (F0-F4; F0=no fibrosis; F4= cirrhosis). The mean age of patients was 42 +/- 8 years, 61% were male and 36% consumed > 50 g of alcohol daily. The mean duration of infection was 19 +/- 9 years (range, 1-40) and ALT was elevated > 1.5 times upper normal in 63%. When patients were classified into those with mild (F0-F2) and severe (F3-F4) fibrosis, the sensitivity, specificity, positive predictive value and negative predictive value of an estimate of mild fibrosis was 60%, 55%, 78% and 34%, respectively. An estimate of severe fibrosis had a sensitivity of 55%, specificity of 60%, positive predictive value of 34% and negative predictive value of 78%. Agreement between fibrosis estimates and actual histological stages was poor (kappa = 0.13, P=0.08). The prediction of hepatic fibrosis in HCV infection using historical features and published rates of fibrosis progression is poor in a Canadian clinical practice setting. Alternate noninvasive methods of predicting hepatic fibrosis are needed.


Subject(s)
Hepatitis C, Chronic/complications , Liver Cirrhosis/etiology , Liver/pathology , Adult , Age of Onset , Aged , Canada , Disease Progression , Female , Hepatitis C, Chronic/pathology , Humans , Liver Cirrhosis/pathology , Male , Middle Aged , Prognosis , Recurrence , Risk Factors , Treatment Outcome
13.
Am J Gastroenterol ; 96(6): 1849-53, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11419838

ABSTRACT

OBJECTIVE: To examine the smoking behaviors of people with Crohn's disease. In active smokers, we measured their willingness to quit, their degree of nicotine dependence, and the proportion that made a quit attempt within 6 months to determine if they were refractory to smoking cessation in comparison to the general population. We also examined factors that were important in their decision to smoke. METHODS: We conducted a cross-sectional survey of out-patients, supplemented by telephone interviews and a 6-month follow-up questionnaire of active smokers. Measures included disease activity, current smoking behaviors, intentions (stage of change), Fagerstrom Test for Nicotine Dependence, and factors related to their decision to smoke (decisional balance). RESULTS: The questionnaire was completed by 115 patients (78% response rate). Forty percent were active smokers. Of active smokers, 59% were considering quitting within the next 6 months, and of these, 15% were planning on quitting within the next 30 days. Those with moderate disease activity were more likely to be considering quitting than those with mild or severe activity. Nicotine dependence was rated as high in 33% and as moderate in 43%. Factors unrelated to Crohn's disease were more important in their decision to smoke than were Crohn's disease-related factors. After 6 months, 23% had made an attempt to quit and this attempt was strongly associated with their stated intentions at the baseline questionnaire. Two of three patients who had recently quit at baseline had resumed smoking. CONCLUSION: When compared to similar data for the general population, patients with Crohn's disease are no more refractory to smoking cessation.


Subject(s)
Attitude , Crohn Disease/psychology , Smoking Cessation/psychology , Adult , Aged , Cross-Sectional Studies , Decision Making , Female , Follow-Up Studies , Humans , Male , Middle Aged , Outpatients , Tobacco Use Disorder
14.
BMC Med Res Methodol ; 1: 13, 2001.
Article in English | MEDLINE | ID: mdl-11801192

ABSTRACT

BACKGROUND: The Digestive Diseases Week (DDW) is the major meeting for presentation of research in gastroenterology. The acceptance of an abstract for presentation at this meeting is the most important determinant of subsequent full publication. We wished to examine the determinants of abstract acceptance for this meeting. METHODS: A cross-sectional study was performed, based on abstracts submitted to the DDW. All 17,205 abstracts submitted from 1992 to 1995 were reviewed for acceptance, country of origin and research type (controlled clinical trials (CCT), other clinical research (OCR), basic science (BSS)). A random sub-sample (n = 1,000) was further evaluated for formal abstract quality, statistical significance of study results and sample size. RESULTS: 326 CCT, 455 OCR and 219 BSS abstracts were evaluated in detail. Abstracts from N/W Europe (OR 0.4, 95% CI 0.3-0.6), S/E Europe (OR 0.4, 95% CI 0.2-0.6) and non-Western countries (OR 0.3, 95% CI 0.2-0.5) were less likely to be accepted than North-American contributions when controlling for research type. In addition, the OR for the acceptance for studies with negative results as compared to those with positive results was 0.4 (95% CI 0.3-0.7). A high abstract quality score was also weakly associated with acceptance rates (OR 1.4, 95% CI 1.0-2.0). CONCLUSIONS: North-American contributions and reports with statistically positive results have higher acceptance rates at the AGA. Formal abstract quality was also predictive for acceptance.


Subject(s)
Gastroenterology/organization & administration , Gastroenterology/standards , Peer Review/standards , Research Design/standards , Abstracting and Indexing/standards , Abstracting and Indexing/trends , Cross-Sectional Studies , Humans , North America , Western World
15.
Am J Gastroenterol ; 95(2): 352-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10685735

ABSTRACT

Smoking is not only a risk factor for Crohn's disease, but ongoing smoking is associated with a poorer disease course. Therefore, smoking cessation should be an important treatment strategy for Crohn's disease patients who smoke tobacco. Recent improvements in understanding how people quit smoking and the development of pharmacological interventions, such as nicotine patches and bupropion, have improved cessation rates. In this article, we first briefly review the evidence supporting the adverse effects of smoking on the disease course. We next review the current understanding of how people change addictive behaviors, such as smoking. We then describe how the gastroenterologist can aid the patient with Crohn's disease to quit smoking, including appropriate and brief counseling strategies and the use of adjunctive treatments. Given the improvements in smoking cessation strategies, all patients with Crohn's disease should be strongly advised to quit smoking and be aided in doing so.


Subject(s)
Crohn Disease/complications , Smoking Cessation , Administration, Cutaneous , Behavior, Addictive/prevention & control , Behavior, Addictive/psychology , Bupropion/therapeutic use , Counseling , Dopamine Uptake Inhibitors/therapeutic use , Humans , Nicotine/administration & dosage , Nicotine/therapeutic use , Nicotinic Agonists/administration & dosage , Nicotinic Agonists/therapeutic use , Risk Factors , Smoking/adverse effects , Smoking/psychology , Smoking Prevention
16.
Neurology ; 53(9): 2093-6, 1999 Dec 10.
Article in English | MEDLINE | ID: mdl-10599787

ABSTRACT

BACKGROUND: Prednisone and methylprednisolone are well absorbed orally and have lower treatment costs than IV methylprednisolone, but concern that low-dose corticosteroid may cause increased disease activity and that high oral doses may cause gastric ulceration inhibits use of oral therapy for MS attacks. METHODS: Gastric mucosal injury, detected by measurement of gastric permeability, was examined after five alternate day doses of IV methylprednisolone (1 g) or oral prednisone (1,250 mg) in 21 patients with MS. A triple sugar test solution was consumed at bedtime, and urine was collected overnight. Urine sugar concentrations were determined by high-pressure liquid chromatography. Gastric permeability was expressed as total mg of sucrose excreted. RESULTS: Seventeen patients completed the protocol (12 oral, 5 IV). Baseline sucrose excretion was normal in all. Both groups demonstrated an increase in gastric permeability after steroid treatment, but there was no difference between the two groups (95% CI 95 to 91 mg, p = 0.96). After treatment, three (25%) patients in the oral group, and two (40%) patients the IV group, had modestly abnormal gastric permeability (95% CI 34 to 64%, P = 0.6). CONCLUSIONS: Short-term high-dose oral prednisone is not associated with greater gastric damage, as measured with permeability tests, than IV methylprednisolone. High-dose oral prednisone should be considered a first-line treatment option for MS attacks.


Subject(s)
Anti-Inflammatory Agents/adverse effects , Multiple Sclerosis/drug therapy , Prednisone/adverse effects , Stomach Ulcer/chemically induced , Administration, Oral , Adult , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/economics , Cell Membrane Permeability/drug effects , Cost-Benefit Analysis , Dose-Response Relationship, Drug , Female , Gastric Mucosa/drug effects , Humans , Male , Middle Aged , Multiple Sclerosis/economics , Prednisone/administration & dosage , Prednisone/economics , Pulse Therapy, Drug , Stomach Ulcer/economics
17.
Stat Med ; 18(19): 2593-603, 1999 Oct 15.
Article in English | MEDLINE | ID: mdl-10495458

ABSTRACT

The increasing use of constructed scales and indices in clinical science has preceded in many cases a clear understanding of how to appraise the importance of the differences or changes that are thereby observed. For example, in the design of clinical trials which employ such scales as outcome measures it may be difficult to specify what constitutes a clinically significant shift in means, a key factor in sample size calculations. Determination of the minimum important difference relative to specific outcome measures has historically been based on informal and/or intuitive arguments. In this paper we propose a formal statistical framework for these considerations, based on a previously published validation study design which captures patients' perceptions in comparative self-reported assessments. We begin by adopting a mixed-effect model to represent the comparative assessments as composites of individual self-ratings on an underlying continuous scale. We then present two basic approaches for assessing the relation between the hypothesized latent scale and the outcome scale(s) under consideration, taking the latent scale as a plausible benchmark against which observable changes on the outcome scale can be judged.


Subject(s)
Health Status , Models, Statistical , Outcome Assessment, Health Care/methods , Clinical Trials as Topic , Crohn Disease/physiopathology , Humans , Research Design
18.
Can J Gastroenterol ; 13(4): 327-32, 1999 May.
Article in English | MEDLINE | ID: mdl-10360993

ABSTRACT

OBJECTIVES: To determine the degree and determinants of the use of complementary and alternative medicine (CAM) by patients with inflammatory bowel disease (IBD) with the use of the Internet and to compare the results with those found by using a similar survey in patients attending gastroenterology clinics in Calgary, Alberta. SUBJECTS AND METHODS: A cross-sectional survey of 263 patients with IBD with the use of a World Wide Web-based, structured questionnaire was conducted. RESULTS: Complementary therapies had been used by 46% of patients in the previous two years. Current use was reported by 34%. Vitamins, herbal products and natural health practices were the most commonly reported therapies. Side effects and lack of effectiveness of standard therapies were the most commonly cited reasons for seeking complementary medicine. However, despite this, respondents who had previously received surgery, or intravenous or oral steroids were less likely to be current CAM users. Important differences between the determinants of and reasons for CAM use in the present study and those of a similar study of IBD patients in a local tertiary care setting were noted. CONCLUSIONS: Complementary medicine use is common in patients with IBD. Differences in the determinants of and reasons for CAM use noted between the present Internet sample and a gastroenterology clinic sample suggest that conclusions from the present study and from previous studies based only on clinic samples provide a limited view of CAM use by people with IBD. More comprehensive assessments are needed.


Subject(s)
Complementary Therapies/statistics & numerical data , Inflammatory Bowel Diseases/therapy , Adult , Alberta , Complementary Therapies/methods , Cross-Sectional Studies , Data Collection , Female , Humans , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/physiopathology , Internet , Male , Middle Aged , Patient Compliance , Patient Satisfaction , Surveys and Questionnaires , Treatment Outcome
19.
Inflamm Bowel Dis ; 5(2): 85-91, 1999 May.
Article in English | MEDLINE | ID: mdl-10338376

ABSTRACT

A method of detecting presymptomatic relapse of Crohn's disease could allow for the selective use of maintenance or intensified medical therapy in those with an increased risk of relapse. The aim of this study was to evaluate three potential laboratory markers of relapse: intestinal and gastroduodenal permeability and plasma diamine oxidase activity. Intestinal permeability (lactulose/mannitol test), gastroduodenal permeability (urinary sucrose excretion), and postheparin plasma diamine oxidase activity were serially measured in 61 adults with Crohn's disease in remission (CDAI <150) for at least 30 days. Subjects were followed periodically for clinical relapse (CDAI >150 and increased by at least 100 points or the need for steroids or surgery). Fourteen patients (23%) relapsed. A cut-off of 0.030 for the lactulose/mannitol ratio was defined. Those with ratios above the cutoff had a 7.0 times greater risk of relapse (p<0.001). Three subjects who went from a normal ratio to an abnormal ratio relapsed, whereas none of 32 subjects with a repeatedly normal ratio relapsed. Sucrose excretion and plasma diamine oxidase activity did not predict relapse. Serial testing of intestinal permeability, but not of gastroduodenal permeability or plasma diamine oxidase activity, was useful in predicting relapse in asymptomatic patients.


Subject(s)
Amine Oxidase (Copper-Containing)/blood , Crohn Disease/epidemiology , Intestinal Absorption/physiology , Adult , Cohort Studies , Crohn Disease/diagnosis , Female , Heparin , Humans , Male , Permeability , Predictive Value of Tests , Prospective Studies , Recurrence , Time Factors
20.
Can J Gastroenterol ; 13(1): 31-6, 1999.
Article in English | MEDLINE | ID: mdl-10099814

ABSTRACT

BACKGROUND: Members of a subset of first-degree relatives of adults with Crohn's disease have been shown to have an increased baseline intestinal permeability and/or an exaggerated increase in intestinal permeability after the administration of acetylsalicylic acid. PURPOSE: To determine intestinal permeability in unaffected first-degree relatives of children with Crohn's disease before and after the administration of an ibuprofen challenge. METHODS: Lactulose-mannitol ratios, a measure of intestinal permeability, were determined in 14 healthy control families (41 subjects) and 14 families with a child with Crohn's disease (36 relatives, 14 probands) before and after ingestion of ibuprofen. An upper reference limit was defined using the control group as mean +/- 2 SD. RESULTS: The proportion of healthy, first-degree relatives with an exaggerated response to ibuprofen (20%, 95% CI 7% to 33%) was significantly higher than controls (P = 0.003). The exaggerated response was more common among siblings than among parents of pediatric probands. CONCLUSIONS: Members of a subset of first-degree relatives of children with Crohn's disease have an exaggerated increase in intestinal permeability after ibuprofen ingestion. These findings are compatible with there being a genetic link between abnormalities of intestinal permeability and Crohn's disease.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Crohn Disease/genetics , Ibuprofen/pharmacology , Intestinal Absorption/drug effects , Adolescent , Adult , Crohn Disease/physiopathology , Female , Humans , Intestinal Absorption/genetics , Lactulose , Male , Mannitol , Permeability
SELECTION OF CITATIONS
SEARCH DETAIL
...